Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population studyAntonietta Romano, A. Albertí, Paolo Angeli et al.|Journal of Hepatology|2018Cited by 166
THU-131-Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: A real-life study from the NAVIGATORE Lombardia and Veneto NetworksElisabetta Degasperi, S. Fagiuoli, Angiola Spinetti et al.|Journal of Hepatology|2019Cited by 3
Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto NetworksElisabetta Degasperi, S. Fagiuoli, Angiola Spinetti et al.|Digestive and Liver Disease|2019Cited by 1
Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study GroupElisabetta Degasperi, S. Fagiuoli, Massimo Zuin et al.|Digestive and Liver Disease|2018Cited by 0
Effectiveness and safety of DAA treatment for recurrent hepatitis C after liver transplantation: The NAVIGATOR Lombardia-Veneto networkFederica Invernizzi, S. Fagiuoli, L. Pasulo et al.|Digestive and Liver Disease|2018Cited by 0